Chronic Hepatitis C and Iron Overload Syndrome

E.Z. Burnevich, M.V. Severov, M.M Severova

Abstract


The article deals with the questions of pathogenesis and treatment of iron overload syndrome in patients with chronic viral hepatitis C. The usage of peg-IFN-α and ribaverin combination as well as phlebotomy as an adjuvant component of antiviral therapy have been considered.


Keywords


chronic hepatitis; iron overload syndrome; therapy; phlebotomy

References


Simin M., Brok J., Stimac D. et al. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C // Aliment. Pharmacol. Ther., 2007, 25, 1153-1162.

Tungol A., Rademacher K., Schafer J.A. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus // J. Manag. Care Pharm., 2011, 17, 685-694.

El-Zayadi A.R. Hepatitis C comorbidities affecting the course and response to therapy // World J. Gastroenterol., 2009, 15, 4993-4999.

Price L., Kowdley K.V. The role of iron in the pathophysiology and treatment of chronic hepatitis C // Can J. Gastroenterol., 2009, 23, 822-828.

Massard J., Ratziu V., Thabut D. et al. Natural history and predictors of disease severity in chronic hepatitis C // J. Hepatol., 2006, 44 (Suppl.), S19-S24.

Fujita N., Sugimoto R., Urawa N. et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C // J. Gastroenterol. Hepatol., 2007, 22, 1886-1893.

Haque S., Chandra B., Gerber M.A., Lok A.S. Iron overload in patients with chronic hepatitis C: a clinicopathologic study // Hum. Pathol., 1996, 27, 1277-1281.

Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., Bacon B.R. Measurements of iron status in patients with chronic hepatitis // Gastroenterology, 1992, 102, 2108-2113.

Hezode C., Cazeneuve C., Coue O. et al. Liver iron accumulation in patients with chronic active hepatitis C: Prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions // J. Hepatol., 1999, 31, 979-984.

Silva I.S., Perez R.M., Oliveira P.V. et al. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study // J. Gastroenterol. Hepatol., 2005, 20, 243-248.

Alla V., Bonkovsky H.L. Iron in nonhemochromatotic liver disorders // Semin. Liver Dis., 2005, 25, 461-472.

Choi J., Ou J.H. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus // Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G847-G851.

Isomura T., Yano M., Hayashi H., Sakamoto N. Excess iron in the liver of patients with chronic hepatitis C // J. Clin. Electron. Microsc., 1992, 25, 231-237.

Fujita N., Horiike S., Sugimoto R. et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients // Free Radic. Biol. Med., 2007, 42, 353-362.

Furutani T., Hino K., Okuda M. et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein // Gastroenterology, 2006, 130, 2087-2098.

Chapoutot C., Esslimani M., Joomaye Z. et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis // Gut, 2000, 46, 711-714.

Ko C., Siddaiah N., Berger J. et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: Results from the National Hemochromatosis Transplant Registry // Liver Int., 2007, 27, 1394-1401.

Nishina S., Hino K., Korenaga M. et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription // Gastroenterology, 2008, 134, 226-238.

Fujita N., Sugimoto R., Takeo M. et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C // Mol. Med., 2007, 13, 97-104.

Saito H., Fujimoto Y., Ohtake T. et al. Up-regulation of transferrin receptor 1 in chronic hepatitis C: implication in excess hepatic iron accumulation // Hepatol. Res., 2005, 31, 203-210.

Trinder D., Ayonrinde O.T., Olynyk J.K. HCV, iron, and oxidative stress: The new choreography of hepcidin // Gastroenterology, 2008, 134, 348-351.

Theurl I., Zoller H., Obrist P. et al. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3 // J. Infect. Dis., 2004, 190, 819-825.

Bassett S.E., Di Bisceglie A.M., Bacon B.R. et al. Effects of iron loading on pathogenicity in hepatitis C virusinfected chimpanzees // Hepatology, 1999, 29, 1884-1892.

Furutani T., Hino K., Okuda M. et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein // Gastroenterology, 2006, 130, 2087-2098.

Sartori M., Andorno S., Rigamonti C. et al. Chronic hepatitis C is mild in menstruating women // J. Gastroenterol. Hepatol., 2000, 15, 1411-1417.

Guyader D., Thirouard A.S., Erdtmann L. et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C // J. Hepatol., 2007, 46, 587-595.

Lange C.M., Kutalik Z., Morikawa K. et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-α and ribavirin therapy // Hepatology, 2011 (article in press).

Bonkovsky H.L., Naishadham D., Lambreacht R.W. et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C // Gastroenterology, 2006, 131, 1440-1451.

Tung B.Y., Emond M.J., Bronner M.P. et al. Hepatitis C, iron status, and disease severity: Relationship with HFE mutations // Gastroenterology, 2003, 124, 318-326.

Geier A., Reugels M., Weiskirchen R. et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C // Liver Int., 2004, 24, 285-294.

Chevaliez S., Pawlotsky J.-M. Interferon-based therapy of hepatitis C // Adv. Drug Deliv. Rev., 2007, 59, 1222-1241.

Torti F.M., Torti S.V. Regulation of ferritin genes and protein // Blood, 2002, 99, 3505-3516.

Ladero J.M., López-Alonso G., Devesa M.J. et al. Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C // Rev. Esp. Enferm. Dig., 2009, 101,

-40.

Ferrara F., Ventura P., Vegetti A. et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C // Am. J. Gastroenterol., 2009, 104, 605-616.

Eisenbach C., Gehrke S.G., Stremmel W. Iron, the HFE gene, and hepatitis C // Clin. Liver Dis., 2004, 8, 775-785.

Olynyk J.K., Reddy K.R., Di Bisceglie A.M. et al. Hepatic iron concentration as a predictor of response to interferon-alfa therapy in chronic hepatitis C // Gastroenterology, 1995, 108, 1104-1119.

Van Thiel D.H., Friedlander L., Fagiuoli S. et al. Response to interferon alpha therapy is influenced by the iron content of the liver // J. Hepatol., 1994, 20, 410-415.

Ikura Y., Morimoto H., Johmura H. et al. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C // Am. J. Gastroenterol., 1996, 91, 1367-1373.

Fujita N., Sugimoto R., Urawa N. et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C // J. Gastroenterol. Hepatol., 2007, 22, 1886-1893.

Pereira Pda S., Silva I.S., Uehara S.N. et al. Chronic hepatitis C: hepatic iron content does not correlate with response to antiviral therapy // Rev. Inst. Med. Trop. Sao Paulo, 2009, 51, 331-336.

Sikorska K., Stalke P., Izycka-Swieszewska E. et al. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C // Med. Sci. Monit., 2010, 16, 137-143.

Ishizu Y., Katano Y., Honda T. et al. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C // J. Gastroenterol. Hepatol., 2011, 24, 134-139.

Carneiro M.V., Souza F.F., Teixeira A.C. et al. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C // Eur. J. Gastroenterol. Hepatol., 2010, 22, 1204-1210.

Tandon N., Thaker V., Kumkar R. et al. Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease // British J. Nutr., 2000, 83, 235-239.

Sumida Y., Kanemasa K., Fukumoto K. et al. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: Results from a randomized, controlled trial on 40 Japanese patients // Intern. Med., 2007, 46, 637-642.

Hayashi H., Takikawa T., Nishimura N. et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C // Am. J. Gastroenterol., 1994, 89,

-988.

Di Bisceglie A.M., Bonkovsky H.L., Chopra S. et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial // Hepatology, 2000, 32, 135-138.

Yano M., Hayashi H., Yoshioka K. et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan // J. Gastroenterol., 2004, 39, 570-574.

Yano M., Hayashi H., Wakusawa S. et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C // Am. J. Gastroenterol., 2002, 97, 133-137.

Fontana R.J., Israel J., LeClair P. et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial // Hepatology, 2000, 31, 730-736.

Fargion S., Fracanzani A.L., Rossini A. et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: Results of an Italian multicenter randomized study // Am. J. Gastroenterol., 2002, 97, 1204-1210.

Tsai N., Zuckerman E., Han S.H. et al. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy // Am. J. Gastroenterol., 1997, 92, 1831-1834.

Sartori M., Andorno S., Rossini A. et al. Phlebotomy improves histology in chronic hepatitis C males with mild iron overload // World J. Gastroenterol., 2010, 16, 596-602.

Sartori M., Andorno S., Rossini A. et al. A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C // Eur. J. Gastroenterol. Hepatol., 2011, 23, 1178-1184.

Fong T.L., Han S.H., Tsai N.C. et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C // J. Hepatol., 1998, 28, 369-374.

Carlo C., Daniela P., Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C // Hepatol. Gastroenterol., 2003, 50, 1467-1471.

Piperno A., Vergani A., Malosio D. et al. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations // Hepatology, 1998, 28, 1105-1109.

Desai T.K., Jamil L.H., Balasubramaniam M. et al. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: A meta-analysis of six prospective randomized controlled trials // Dig. Dis. Sci., 2008, 53, 815-822.

Van Thiel D.H., Friedlander L., Molloy P.J. et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy // Hepatogastroenterology, 1996, 43, 1557-1561.

Di Bisceglie A.M., Bonkovsky H.L., Chopra S. et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial // Hepatology, 2000, 32, 135-138.

Guyader D., Boucher E., Andre P. et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon // Am. J. Gastroenterol., 1999, 94, 1696-1698.

Alexander J., Tung B.Y., Croghan A., Kowdley K.V. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: Results of a pilot study // Liver Int., 2007, 27, 268-273.

Coelho-Borges S., Cheinquer H., Cheinquer N. et al. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload // Am. J. Gastroenterol., 2002, 97, 1570-1572.

Bonkovsky H.L., Naishadham D., Lambreacht R.W. et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C // Gastroenterology, 2006, 131, 1440-1451.

Gentile I., Viola C., Paesano L. et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial // J. Clin. Apher., 2009, 24, 190-196.

Kato J., Miyanishi K., Kobune M. et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C // J. Gastroenterol., 2007, 42, 830-836.




DOI: https://doi.org/10.22141/2308-2097.2.52.2014.81967

Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта